Current Report Filing (8-k)
September 05 2017 - 5:06AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
Current Report
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report
(Date of earliest event reported):
September 1, 2017
CYTORI THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
|
|
|
Delaware
|
001-34375
|
33-0827593
|
(State or Other Jurisdiction of Incorporation)
|
(Commission File
Number)
|
(I.R.S. Employer Identification Number)
|
3020 Callan Road, San Diego, California 92121
(Address of principal executive offices, with zip code)
(858) 458-0900
(Registrant's telephone number, including area code)
n/a
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (
see
General Instruction A.2. below):
|
|
|
|
□
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
|
|
□
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
|
|
□
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
|
|
□
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate
by
check
mark whether
the
registrant
is
a
n
emerging
growth
company
as
defined
in as
defined
in
Rule
405
of the
Securities
Act
of
1933
(§
230.405
of
this
chapter)
or
Rule
12b-2
of
the
Securities
Exchange
Act
of
1934
(§
240.12b-2
of
this
chapter). Emerging
growth
company
□
If
an
emerging
growth
company,
indi
c
a
te
by
check
mark
if
the
registrant
has
elected
not to use the
e
x
tended
transition
period
for complying
with
any
new
or
re
v
ised
financial
accounting
standards
pro
v
ided
pursuant
to
Section
13(a)
of
the
E
x
change
Act.
□
Item
8.01
Other Events
On September 1, 2017, Cytori Therapeutics, Inc. (the “Company”) announced a corporate restructuring intended to significantly reduce expenses. The restructuring is expected to reduce the Company’s workforce by approximately 50%.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
CYTORI THERAPEUTICS, INC.
|
|
|
Date: September 1, 2017
|
By: /s/ Tiago Girao
|
|
Tiago Girao
|
|
VP Finance and Chief Financial Officer
|
Cytori Therapeutics (NASDAQ:CYTX)
Historical Stock Chart
From Apr 2024 to May 2024
Cytori Therapeutics (NASDAQ:CYTX)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about Cytori Therapeutics Inc (NASDAQ): 0 recent articles
More Cytori Therapeutics, Inc. News Articles